Timing of androgen-deprivation therapy in prostate cancer

Affiliations

Comment

Lakshminarayanan Nandagopal. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):e634.

doi: 10.1016/S1470-2045(17)30775-1. Epub 2017 Oct 31.

¹ University of Alabama at Birmingham, Birmingham, 35294 AL, USA. Electronic address: dr.n.lakshminarayanan@gmail.com.

No abstract available

Comment in

Timing of androgen-deprivation therapy in prostate cancer - Author's reply.
Duchesne GM, Woo HH. Duchesne GM, et al. Lancet Oncol. 2017 Nov;18(11):e635. doi: 10.1016/S1470-2045(17)30799-4. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208389 No abstract available.

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, D'Este C, Frydenberg M, Loblaw A, Malone S, Millar J, Tai KH, Turner S. Duchesne GM, et al. Lancet Oncol. 2017 Sep;18(9):1192-1201. doi: 10.1016/S1470-2045(17)30426-6. Epub 2017 Jul 28. Lancet Oncol. 2017. PMID: 28760403 Clinical Trial.